964
Views
27
CrossRef citations to date
0
Altmetric
Review

The locus of microRNA-10b

A critical target for breast cancer insurgence and dissemination

, , , , &
Pages 2371-2375 | Received 10 May 2013, Accepted 12 Jun 2013, Published online: 26 Jun 2013

Figures & data

Figure 1. miR-10b locus localization (A) Chromosome 2 representation, where the blue bar indicates miR-10b position in the long arm of Chr2 (figure modified from UCSC genome browser: http://genome.ucsc.edu). (B) Overview of HOXD cluster contains miR-10b precursor.

Figure 1. miR-10b locus localization (A) Chromosome 2 representation, where the blue bar indicates miR-10b position in the long arm of Chr2 (figure modified from UCSC genome browser: http://genome.ucsc.edu). (B) Overview of HOXD cluster contains miR-10b precursor.

Figure 2. miR-10b locus is involved in breast tumorigenesis. (A) In metastatic tumors, miR-10b is overexpressed by Twist transcription. This feature is closely related to the activation of invasive program through downregulation of HOXD10 and consequently overexpression of several cell migration repressor such as RhoC, uPAR, and MMP14.Citation19 (B) In primary breast tumors miR-10b* is downregulated by CpG island hypermethylation. This feature leads to upregulation of its target genes, such as BUB1, PLK1, and CCNA2 and, in turn, to tumor proliferation.Citation27

Figure 2. miR-10b locus is involved in breast tumorigenesis. (A) In metastatic tumors, miR-10b is overexpressed by Twist transcription. This feature is closely related to the activation of invasive program through downregulation of HOXD10 and consequently overexpression of several cell migration repressor such as RhoC, uPAR, and MMP14.Citation19 (B) In primary breast tumors miR-10b* is downregulated by CpG island hypermethylation. This feature leads to upregulation of its target genes, such as BUB1, PLK1, and CCNA2 and, in turn, to tumor proliferation.Citation27

Figure 3. Association between disease-specific survival and the expression levels of miR-10b* and 3 of its target genes (BUB1, PLK1, and CCNA2). (A) Kaplan-Meier analysis based on the METABRIC miR expression data.Citation43 Survival of the 370 patients with the highest (top third) expression levels of miR-10b* (red line) was compared with the 370 patients with the lowest expression levels (blue line). The plot was truncated at 15 y, P value is indicated in the title. (B–D) Kaplan-Meier analysis based on the METABRIC mRNA expression data.Citation42 The 2 compared groups are 565 patients with the highest (top third) expression levels of each target gene (red line) vs. 565 patients with the lowest (bottom third) expression levels (blue line). The plot was truncated at 15 y, P values are indicated in the titles. Only patients with available clinical follow-up were included in this analysis.

Figure 3. Association between disease-specific survival and the expression levels of miR-10b* and 3 of its target genes (BUB1, PLK1, and CCNA2). (A) Kaplan-Meier analysis based on the METABRIC miR expression data.Citation43 Survival of the 370 patients with the highest (top third) expression levels of miR-10b* (red line) was compared with the 370 patients with the lowest expression levels (blue line). The plot was truncated at 15 y, P value is indicated in the title. (B–D) Kaplan-Meier analysis based on the METABRIC mRNA expression data.Citation42 The 2 compared groups are 565 patients with the highest (top third) expression levels of each target gene (red line) vs. 565 patients with the lowest (bottom third) expression levels (blue line). The plot was truncated at 15 y, P values are indicated in the titles. Only patients with available clinical follow-up were included in this analysis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.